Megens A A, Artois K, Vermeire J, Meert T, Awouters F H
Department of Pharmacology, Janssen Research Foundation, Beerse, Belgium.
J Pain Symptom Manage. 1998 Apr;15(4):253-7. doi: 10.1016/s0885-3924(97)00371-0.
Clinical studies report a low incidence of intestinal side effects with transdermally administered fentanyl (TTS-fentanyl) in comparison with oral morphine. To support these clinical data, analgesic and intestinal effects of both opioids were compared in rats. After subcutaneous injection, analgesia in the tail withdrawal reaction test was obtained at a peak effect dose of 0.032 mg/kg with fentanyl and 8.0 mg/kg with morphine. This analgesic dose exceeded the ED50 for inhibition of castor oil-induced diarrhea only slightly (1.1 x) in the case of fentanyl (0.028 mg/kg) but markedly (36 x) in the case of morphine (0.22 mg/kg). To reverse completely the antidiarrheal effect of equivalent analgesic doses of the opioids (their ED50S for analgesia lasting 2 hours), much more naloxone was required in the case of morphine (5.4 mg/kg) than in the case of fentanyl (0.19 mg/kg). After oral administration, the difference between both opioids was less pronounced. Analgesia was obtained at 0.85 mg/kg with fentanyl and 32 mg/kg with morphine. This analgesic dose only slightly (1.7 x) exceeded the antidiarrheal dose in the case of fentanyl (0.49 mg/kg) but significantly (6.2 x) in the case of morphine (5.2 mg/ kg). To reverse completely the antidiarrheal effect of equivalent analgesic oral doses of the opioids (their ED50S for analgesia lasting 2 hours), more naloxone was required in the case of morphine (11 mg/kg) than in the case of fentanyl (2.0 mg/kg). Rapid penetration of fentanyl into the brain is thought to be responsible for small dissociation between the analgesic and intestinal effect of this lipophilic opioid. The present data provide preclinical evidence to support the relatively low incidence of intestinal side effects observed clinically with the use of TTS-fentanyl in comparison with orally administered morphine.
临床研究报告称,与口服吗啡相比,经皮给药芬太尼(透皮芬太尼)引起肠道副作用的发生率较低。为了支持这些临床数据,在大鼠中比较了两种阿片类药物的镇痛和肠道效应。皮下注射后,在甩尾反应试验中,芬太尼的峰值效应剂量为0.032mg/kg,吗啡为8.0mg/kg时可获得镇痛效果。该镇痛剂量仅略高于(1.1倍)芬太尼(0.028mg/kg)抑制蓖麻油诱导腹泻的半数有效剂量(ED50),但显著高于(36倍)吗啡(0.22mg/kg)的ED50。为了完全逆转等效镇痛剂量的阿片类药物(其镇痛ED50持续2小时)的止泻作用,吗啡(5.4mg/kg)比芬太尼(0.19mg/kg)需要更多的纳洛酮。口服给药后,两种阿片类药物之间的差异不太明显。芬太尼0.85mg/kg、吗啡32mg/kg时可获得镇痛效果。该镇痛剂量仅略高于(1.7倍)芬太尼(0.49mg/kg)的止泻剂量,但显著高于(6.2倍)吗啡(5.2mg/kg)的止泻剂量。为了完全逆转等效口服镇痛剂量的阿片类药物(其镇痛ED50持续2小时)的止泻作用,吗啡(11mg/kg)比芬太尼(2.0mg/kg)需要更多的纳洛酮。芬太尼迅速渗透到大脑中被认为是这种亲脂性阿片类药物镇痛和肠道效应之间解离较小的原因。目前的数据提供了临床前证据,以支持与口服吗啡相比,临床使用透皮芬太尼时观察到的肠道副作用发生率相对较低。